<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676634</url>
  </required_header>
  <id_info>
    <org_study_id>rBV A/B-CL-002</org_study_id>
    <nct_id>NCT03676634</nct_id>
  </id_info>
  <brief_title>Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®</brief_title>
  <official_title>Tolerability and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers With Existing Botulinum Immunity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Department of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>California Department of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2, open-label, uncontrolled study designed to evaluate safety, tolerability, and&#xD;
      immunogenicity of a single dose of rBV A/B in healthy participants previously immunized with&#xD;
      pentavalent botulinum toxoid (or pentavalent botulinum toxoid and rBV A/B) for occupational&#xD;
      protection will be conducted to collect source plasma for potential use in the production of&#xD;
      BabyBIG and to evaluate safety and immunogenicity of the vaccine in these participants over a&#xD;
      12-week period, with a follow-up safety assessment at 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2019</start_date>
  <completion_date type="Actual">July 3, 2020</completion_date>
  <primary_completion_date type="Actual">April 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects Achieving Greater Than 3- or 4-Fold Increases in Neutralizing Antibody Concentration (NAC)</measure>
    <time_frame>Week 0 to Week 4</time_frame>
    <description>Neutralizing Antibody Concentration in Plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving Greater Than 2-Fold Increase in Neutralizing Antibody Concentration (NAC)</measure>
    <time_frame>Week 0 to 12</time_frame>
    <description>Neutralizing Antibody Concentration in Plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Volume of Plasma Collected With an Acceptable Anti-type A or Anti-type B Titer</measure>
    <time_frame>Week 0 to 4</time_frame>
    <description>Neutralizing Antibody Concentration in Plasma</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Botulism</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rBV A/B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rBV A/B</intervention_name>
    <description>Recombinant Botulinum Vaccine A/B, rBV A/B</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have received pentavalent botulinum toxoid (or pentavalent botulinum toxoid and rBV&#xD;
             A/B) for occupational protection under BB IND 0161 (or BB-IND-0161 and IND 015155)&#xD;
&#xD;
          2. Be 18 to 69 years old at the time of consent&#xD;
&#xD;
          3. Be healthy and have an acceptable medical history that will not interfere with the&#xD;
             objectives of the study&#xD;
&#xD;
          4. Meet the participant suitability requirements and recommendations for source plasma&#xD;
             donors outlined in Appendix A.&#xD;
&#xD;
          5. If female, and of childbearing potential, have a negative pregnancy test at screening&#xD;
             and within 24 hours prior to vaccination and must not plan to become pregnant until&#xD;
             after the last plasma donation or until the Week 12 visit ([whichever occurs last].&#xD;
&#xD;
          6. Have the ability to understand the requirements of the study, have provided written&#xD;
             informed consent as evidenced by signature on an informed consent form (ICF) approved&#xD;
             by the Committee for the Protection of Human Subjects, and have agreed to abide by the&#xD;
             study restrictions and to return for the required assessments&#xD;
&#xD;
          7. Agree to complete the participant home diary on a daily basis for 7 days post&#xD;
             vaccination, as well as to report any adverse events and concomitant medications&#xD;
             during the study period&#xD;
&#xD;
          8. Have provided written authorization for use and disclosure of protected health&#xD;
             information&#xD;
&#xD;
          9. Agree not to donate blood or blood products (outside of study procedures) until after&#xD;
             the last plasma donation or until the Week 12 visit (whichever occurs last)&#xD;
&#xD;
         10. Have personal health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Be pregnant or nursing&#xD;
&#xD;
          2. Have a history of laboratory evidence of syphilis, acquired immunodeficiency syndrome,&#xD;
             Creutzfeldt-Jakob disease, or infection with human immunodeficiency viruses (HIV) 1 or&#xD;
             2, human T-cell lymphotropic virus 1, hepatitis B virus (HBV), or hepatitis C virus&#xD;
             (HCV)&#xD;
&#xD;
          3. Have had a prior severe (Grade 3 or higher) local or severe (Grade 3 or higher)&#xD;
             systemic reaction to last immunization with pentavalent botulinum toxoid or a prior&#xD;
             severe immediate hypersensitivity reaction or severe systemic reaction to last&#xD;
             vaccination on Day 0 with rBV A/B&#xD;
&#xD;
          4. Have known allergy to aluminum, yeast, or other components of the vaccine&#xD;
&#xD;
          5. Have donated one or more units of blood or undergone plasmapheresis within 49 days of&#xD;
             the Vaccination Visit (Day 0)&#xD;
&#xD;
          6. Have received blood product or immunoglobulin within 6 months prior to study entry or&#xD;
             plans to receive such products during the study period (exclusive of returned red&#xD;
             blood cells as part of the plasmapheresis procedure). For participants who choose to&#xD;
             donate plasma, this will apply until their last plasma donation or at the Week 12&#xD;
             visit (whichever occurs last)&#xD;
&#xD;
          7. Have received licensed nonliving vaccine within 14 days prior to study entry, or&#xD;
             licensed live vaccine within 60 days prior to study entry&#xD;
&#xD;
          8. Have received investigational products (drugs, biologics, vaccines, or implantable&#xD;
             devices) 60 days prior to study entry or plans to receive experimental products at any&#xD;
             time during the study period. For participants who choose to donate plasma, this will&#xD;
             apply until their last plasma donation or at the Week 12 visit (whichever occurs last)&#xD;
&#xD;
          9. Have received prescription immunosuppressive or immunomodulatory agents, including&#xD;
             parenteral, inhaled, or oral corticosteroids within 3 months of study entry or plans&#xD;
             on receiving such therapy at any time during the study period [For participants who&#xD;
             choose to donate plasma, this will apply until their last plasma donation or at the&#xD;
             Week 12 visit (whichever occurs last)], with the exceptions mentioned below&#xD;
&#xD;
               -  Participants who have used prescription topical steroids may be enrolled 2 weeks&#xD;
                  after the therapy is completed&#xD;
&#xD;
               -  Intra-articular, bursal, or tendon injectable steroids are permitted&#xD;
&#xD;
               -  Any over-the-counter topical steroid use is permitted&#xD;
&#xD;
               -  Ophthalmic and intranasal steroids are permitted&#xD;
&#xD;
         10. Have received cytotoxic therapy at any time in the previous 5 years before study entry&#xD;
&#xD;
         11. Have an active systemic or recurrent disease that would place the participant at&#xD;
             unacceptable risk of injury, require hospitalization, or require surgical intervention&#xD;
             (This includes active mental illness or history of mental illness not responsive to&#xD;
             treatment.)&#xD;
&#xD;
         12. Have a history of alcohol or drug abuse or dependence within 12 months of study entry&#xD;
&#xD;
         13. Have past, present, or suspected illicit injection drug use&#xD;
&#xD;
         14. Have inflammatory, vasculitic, or rheumatic disease, including systemic lupus&#xD;
             erythematosus, polymyalgia rheumatica, rheumatoid arthritis, or scleroderma (Stable&#xD;
             osteoarthritis treated with physical therapy and nonsteroidal anti inflammatory drugs&#xD;
             is not an exclusion criterion.)&#xD;
&#xD;
         15. Have any acute or chronic neuromuscular or neurologic disorder&#xD;
&#xD;
         16. Have clinically confirmed hepatic or renal insufficiency&#xD;
&#xD;
         17. Have uncontrolled hypertension, as defined a systolic blood pressure greater than 160&#xD;
             mmHg and diastolic blood pressure greater than 90 mmHg&#xD;
&#xD;
         18. Have moderate to severe asthma, chronic obstructive pulmonary disease, or other&#xD;
             significant pulmonary disease&#xD;
&#xD;
         19. Have a seizure disorder&#xD;
&#xD;
         20. Have moderate or severe illness or oral temperature of 100.4°F or greater within 3&#xD;
             days of Vaccination Visit (Day 0)&#xD;
&#xD;
         21. Be unsuitable for participation in this study for any reason, as assessed by the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Arnon, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Department of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Department of Public Health</name>
      <address>
        <city>Richmond</city>
        <state>California</state>
        <zip>94804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Battelle Biomedical Research Center</name>
      <address>
        <city>West Jefferson</city>
        <state>Ohio</state>
        <zip>43162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <results_first_submitted>August 20, 2021</results_first_submitted>
  <results_first_submitted_qc>September 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2021</results_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulism</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03676634/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03676634/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 32 participants were enrolled during the recruiting period from 07 March 2019 to 29 August 2019.</recruitment_details>
      <pre_assignment_details>All enrolled participants participated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.5 mL rBV A/B</title>
          <description>A single 0.5-mL intramuscular injection of 40 μg of rBV A/B was administered to each participant on Day 0 to stimulate the production of antibodies against botulinum toxin type A and type B.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Screening</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received rBV A/B Injection</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Included in the Plasma-donating Population</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Completed Follow up</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Red blood cell loss</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Out-of-limit pulse</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.5 mL rBV A/B</title>
          <description>A single 0.5-mL intramuscular injection of 40 μg of rBV A/B was administered to each participant on Day 0 to stimulate the production of antibodies against botulinum toxin type A and type B.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" lower_limit="33" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous BabyBIG Plasma Donor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Achieving Greater Than 3- or 4-Fold Increases in Neutralizing Antibody Concentration (NAC)</title>
        <description>Neutralizing Antibody Concentration in Plasma</description>
        <time_frame>Week 0 to Week 4</time_frame>
        <population>Immunogenicity Population: All participants who received rBV A/B, had a baseline NAC, and had at least one post-vaccination immunogenicity assessment up to and including four weeks after administration of rBV A/B</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mL rBV A/B</title>
            <description>A single 0.5-mL intramuscular injection of 40 μg of rBV A/B was administered to each participant on Day 0 to stimulate the production of antibodies against botulinum toxin type A and type B.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving Greater Than 3- or 4-Fold Increases in Neutralizing Antibody Concentration (NAC)</title>
          <description>Neutralizing Antibody Concentration in Plasma</description>
          <population>Immunogenicity Population: All participants who received rBV A/B, had a baseline NAC, and had at least one post-vaccination immunogenicity assessment up to and including four weeks after administration of rBV A/B</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proportion of participants with a ≥4x increase in type A NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".844" lower_limit=".672" upper_limit=".947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants with a ≥3x increase in type A NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".938" lower_limit=".792" upper_limit=".992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants with a ≥4x increase in type B NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".875" lower_limit=".710" upper_limit=".965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of participants with a ≥3x increase in type B NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".906" lower_limit=".750" upper_limit=".980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Consider increase from baseline to post-dose values. Parameter is proportion achieving desired increase (≥ 3x or 4x increase in Type A and Type B NAC).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>single proportion</param_type>
            <param_value>.844</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.672</ci_lower_limit>
            <ci_upper_limit>.947</ci_upper_limit>
            <estimate_desc>Values listed in table are for Type A. Estimated Value for the Estimation Parameter for type B = 0.875. Lower limit = 0.710, upper limit = 0.965</estimate_desc>
            <other_analysis_desc>Proportion of participants achieving ≥ 3x or 4x increase in NAC values was calculated for both Type A and Type B. Primary endpoint was achieved if both Type A and Type B had proportion ≥50%.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving Greater Than 2-Fold Increase in Neutralizing Antibody Concentration (NAC)</title>
        <description>Neutralizing Antibody Concentration in Plasma</description>
        <time_frame>Week 0 to 12</time_frame>
        <population>Immunogenicity Population: All participants who received rBV A/B, had a baseline NAC, and had at least one post-vaccination immunogenicity assessment up to and including four weeks after administration of rBV A/B</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mL rBV A/B</title>
            <description>A single 0.5-mL intramuscular injection of 40 μg of rBV A/B was administered to each participant on Day 0 to stimulate the production of antibodies against botulinum toxin type A and type B.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving Greater Than 2-Fold Increase in Neutralizing Antibody Concentration (NAC)</title>
          <description>Neutralizing Antibody Concentration in Plasma</description>
          <population>Immunogenicity Population: All participants who received rBV A/B, had a baseline NAC, and had at least one post-vaccination immunogenicity assessment up to and including four weeks after administration of rBV A/B</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>two times or greater increase in type A NAC compared with Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".906" lower_limit=".750" upper_limit=".980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>two times or greater increase in type B NAC compared with Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".844" lower_limit=".672" upper_limit=".947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Volume of Plasma Collected With an Acceptable Anti-type A or Anti-type B Titer</title>
        <description>Neutralizing Antibody Concentration in Plasma</description>
        <time_frame>Week 0 to 4</time_frame>
        <population>Plasma-Donating Population: all participants who received rBV A/B and donated at least one plasma unit.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mL rBV A/B</title>
            <description>A single 0.5-mL intramuscular injection of 40 μg of rBV A/B was administered to each participant on Day 0 to stimulate the production of antibodies against botulinum toxin type A and type B.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Plasma Collected With an Acceptable Anti-type A or Anti-type B Titer</title>
          <description>Neutralizing Antibody Concentration in Plasma</description>
          <population>Plasma-Donating Population: all participants who received rBV A/B and donated at least one plasma unit.</population>
          <units>mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total volume of plasma from all donating participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470,102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total volume of plasma from donating participants with any positive titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470,102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total volume of plasma from donating participants with positive anti-A titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470,102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total volume of plasma from donating participants with positive anti-B titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469,411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious AEs (injection site reactions/systemic reactions) were only collected from day 0 - day 7 during the participant diary collection period. For the rest of the study (from day 7 through 12 weeks of site visits and through the week 26 follow up phone call), AEs were only collected if they were SAEs.</time_frame>
      <desc>Mortality, Adverse Events, and Serious Adverse Event definitions are as described on clinicaltrials.gov. Any anticipated or unanticipated events (not included in the serious adverse event table) grouped by organ system, with the number and frequency of such events.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.5 mL rBV A/B</title>
          <description>A single 0.5-mL intramuscular injection of 40 μg of rBV A/B was administered to each participant on Day 0 to stimulate the production of antibodies against botulinum toxin type A and type B.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site erythema</sub_title>
                <description>general disorders and administration site conditions</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>injection site induration</sub_title>
                <description>general disorders and administration site disorders</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>injection site pain</sub_title>
                <description>general disorders and administration site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen S. Arnon, M.D., M.P.H., Chief, Infant Botulism Treatment and Prevention Program</name_or_title>
      <organization>California Department of Public Health</organization>
      <phone>510-231-7600</phone>
      <email>Stephen.Arnon@cdph.ca.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

